Durable benefit and change in TCR clonality with nivolumab in a Lynch syndrome–associated glioma

Germline replication-repair deficient (gRRD) gliomas are exceptional events, and only a few of them have been treated with immune checkpoint inhibitors (ICIs). Contrary to sporadic gliomas, where ICIs have failed to show any objective benefit, the very few patients with gRRD gliomas treated with ICI...

Descripción completa

Detalles Bibliográficos
Autores principales: Cabezas-Camarero, Santiago, Pérez-Alfayate, Rebeca, García-Barberán, Vanesa, Polidura, María Carmen, Gómez-Ruiz, María Natividad, Casado-Fariñas, Isabel, Subhi-Issa, Issa Ahmad, Hernández, José Carlos Plaza, Garre, Pilar, Díaz-Millán, Isabel, Pérez-Segura, Pedro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9185004/
https://www.ncbi.nlm.nih.gov/pubmed/35694191
http://dx.doi.org/10.1177/17588359221100863

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9185004/
https://www.ncbi.nlm.nih.gov/pubmed/35694191
http://dx.doi.org/10.1177/17588359221100863

Ejemplares similares